



- (51) **International Patent Classification:**
C07C 69/753 (2006.01)
- (21) **International Application Number:**
PCT/US2012/069637
- (22) **International Filing Date:**
14 December 2012 (14.12.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/576,448 16 December 2011 (16.12.2011) US
- (71) **Applicant:** GLAXOSMITHKLINE LLC [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102 (US).
- (72) **Inventors; and**
- (71) **Applicants :** HATCHER, Mark Andrew [US/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). JOHNS, Brian Alvin [US/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). MARTIN, Michael Tolar [US/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). TABET, Elie Amine [US/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). TANG, Jun [CN/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US).
- (74) **Agents:** THOMAS, Robert, Steve et al.; GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:



- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** DERIVATIVES OF BETULIN

FIG. 1 Compound 51 has Superior HIV-1 Polymorphism Coverage to Bevirimat



(57) **Abstract:** The present invention relates to compounds characterized by having a structure according to the following Formula I: (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.